Clinical Trials Logo

Clinical Trial Summary

The investigators create organoid from the pancreatic cancer tissue obtained via EUS-FNA and EUS-FNB within the pancreatic cancer diagnostic process. And also the investigators create organoid from the pancreatic cancer tissue obtained after surgery as part of the pancreatic cancer treatment process. Check for the reactivity to anti-cancer drugs through cell viability assay after treating with various anti-cancer drugs, such as anti-cancer drugs used as adjuvant chemotherapy for pancreatic cancer to the organoid. Also, perform genomic analysis on each organoid, and then check if there are any unique genomic mutations for each organoid. By recognizing the relationship between the unique genomic mutations and reactivity to the anti-cancer drug within pancreatic cancer patients eligible for surgery, the investigators aim to strategize appropriate adjuvant chemotherapy after surgery, thus developing a platform to predict the outcomes of each patient.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04736043
Study type Observational
Source Samsung Medical Center
Contact Joo Kyung Park, MD
Phone 82-2-3410-3409
Email mdsophie@gmail.com
Status Recruiting
Phase
Start date January 31, 2021
Completion date January 7, 2026

See also
  Status Clinical Trial Phase
Recruiting NCT06368063 - The Study of Huaier Granule in Postoperative Adjuvant Therapy of Resectable Pancreatic Cancer Phase 4
Not yet recruiting NCT06375928 - EUS-guided Choledochoduodenostomy vs ERCP as First Line in Malignant Distal Obstruction in Resectable Disease (CARPEDIEM-1 Trial) N/A
Recruiting NCT06388967 - Pancreatic Cancer Detection Consortium
Completed NCT05483257 - Molecular Subtyping for Prognosis Evaluation in Resected Pancreatic Adenocarcinoma
Recruiting NCT05287165 - Clinical Trial to Evaluate the Safety and Efficacy of IM96 CAR-T Cells Therapy in Patients With Advanced Digestive System Neoplasms Early Phase 1
Not yet recruiting NCT06287749 - French Assessment of MRD by Liquid Biopsies in PDAC Patients (FRENCH.MRD.PDAC)
Recruiting NCT03977233 - Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer Phase 2
Completed NCT04224402 - Efficacy and Safety of mFOLFIRINOX as Postoperative Chemotherapy for Pancreatic Cancer in Chinese Patients. Phase 2
Terminated NCT03344172 - Pre-Operative Trial (PGHA vs. PGH) for Resectable Pancreatic Cancer Phase 2
Not yet recruiting NCT05479708 - ctDNA-based Minimal Residual Disease Detection for Resected Pancreatic Adenocarcinoma
Not yet recruiting NCT05637567 - Perioperative Platelet Inhibition With Acetylsalicylic Acid in Patients With Resectable Tumors of the Pancreatic Head Phase 2
Recruiting NCT05181605 - Survival Analysis After Neoadjuvant Therapy in Patients With Resectable Pancreatic Cancer and Risk Factors Phase 2/Phase 3